We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+73.06%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$912M
AUM Growth
-$156M
Cap. Flow
-$257M
Cap. Flow %
-28.19%
Top 10 Hldgs %
35.78%
Holding
190
New
54
Increased
34
Reduced
35
Closed
53

Top Buys

Rank Stock Value
1
CRBP icon
Corbus Pharmaceuticals
CRBP
+$8.96M
2
CYTK icon
Cytokinetics
CYTK
+$8.91M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.6M
4
JBIO
Jade Biosciences
JBIO
+$8.03M
5
PYXS icon
Pyxis Oncology
PYXS
+$6.99M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$26.5M
2
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$21.4M
3
XHB icon
State Street SPDR S&P Homebuilders ETF
XHB
+$19.1M
4
NUVL
Nuvalent
NUVL
+$12.5M
5
IRON icon
Disc Medicine
IRON
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 39.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HELP
51
Cybin Inc
HELP
$485M
$5.77M 0.63%
+367,197
New +$5.3M
ATXS
52
CALL
DELISTED
Astria Therapeutics
ATXS
$5.63M 0.62%
+400,000
New +$4.98M
CRVO icon
53
CervoMed
CRVO
$23.9M
$5.53M 0.61%
+237,345
New +$3.17M
SRRK icon
54
Scholar Rock
SRRK
$5.67B
$5.18M 0.57%
+291,701
New +$4.59M
GPCR icon
55
PUT
Structure Therapeutics
GPCR
$3.41B
$5.16M 0.57%
+120,400
New +$5.08M
MRNS
56
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$4.86M 0.53%
537,925
-208,144
-28% -$2.02M
MGNX icon
57
MacroGenics
MGNX
$235M
$4.68M 0.51%
+318,167
New +$4.81M
XENE icon
58
Xenon Pharmaceuticals
XENE
$6.06B
$4.61M 0.51%
+107,187
New +$4.93M
NRIX icon
59
Nurix Therapeutics
NRIX
$2.41B
$4.41M 0.48%
+300,000
New +$3.23M
EYPT icon
60
CALL
EyePoint Inc
EYPT
$1.03B
$4.27M 0.47%
206,500
-184,500
-47% -$4.57M
TRML
61
CALL
DELISTED
Tourmaline Bio
TRML
$4.1M 0.45%
+179,200
New +$6.32M
ALPN
62
CALL
DELISTED
Alpine Immune Sciences Inc
ALPN
$4.08M 0.45%
+103,000
New +$3.04M
WVE icon
63
Wave Life Sciences
WVE
$1.09B
$3.64M 0.4%
+590,088
New +$2.95M
TARS icon
64
CALL
Tarsus Pharmaceuticals
TARS
$2.58B
$3.63M 0.4%
100,000
– –
SLNO
65
CALL
DELISTED
Soleno Therapeutics
SLNO
$3.47M 0.38%
81,100
+59,900
+283% +$2.71M
CABA icon
66
PUT
Cabaletta Bio
CABA
$437M
$3.41M 0.37%
200,000
– –
LRMR icon
67
Larimar Therapeutics
LRMR
$397M
$3.33M 0.36%
438,528
-164,340
-27% -$1.28M
VRDN icon
68
PUT
Viridian Therapeutics
VRDN
$2.09B
$3.13M 0.34%
+178,900
New +$3.47M
IRON icon
69
CALL
Disc Medicine
IRON
$2.96B
$3.09M 0.34%
+49,600
New +$3.22M
JSPR icon
70
Jasper Therapeutics
JSPR
$21M
$3.09M 0.34%
+105,175
New +$1.87M
AMLX icon
71
CALL
Amylyx Pharmaceuticals
AMLX
$2.26B
$3.01M 0.33%
1,060,100
-238,300
-18% -$3.12M
ANVS icon
72
PUT
Annovis Bio
ANVS
$74.4M
$3M 0.33%
251,900
+248,500
+7,309% +$2.71M
AEON icon
73
AEON Biopharma
AEON
$12.9M
$2.99M 0.33%
3,583
– –
ANVS icon
74
CALL
Annovis Bio
ANVS
$74.4M
$2.98M 0.33%
+250,000
New +$2.73M
DFTX
75
Definium Therapeutics
DFTX
$5.78B
$2.8M 0.31%
297,481
-302,519
-50% -$1.72M
1 2
3
4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Ikarian Capital held 190 positions worth $912M, down 15% from $1.07B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Ikarian Capital withdrew a net $257M in Q1 2024, closing 53 positions and reducing 35 holdings. Its most notable exit was argenx, an estimated $26.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, up from 32% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Alnylam Pharmaceuticals worth $7.7M.

  • Ikarian Capital's largest Q1 2024 buy was Alnylam Pharmaceuticals: 51,541 shares worth $7.7M.
  • Ikarian Capital added most to Corbus Pharmaceuticals in Q1 2024, an estimated $8.96M increase.
  • Ikarian Capital's biggest Q1 2024 reduction was Longboard Pharmaceuticals, Inc. Common Stock, cutting an estimated $21.4M.
  • Ikarian Capital fully exited argenx in Q1 2024, selling an estimated $26.5M.
  • Ikarian Capital's ten largest holdings make up 36% of its $912M portfolio in Q1 2024.
  • Ikarian Capital opened 54 new positions and closed 53 in Q1 2024.
  • Ikarian Capital's portfolio value fell 15% quarter-over-quarter to $912M.

Based on Ikarian Capital's 13F filing for Q1 2024, filed 15 May 2024.